Literature DB >> 33571291

Comparison of (Partial) economic evaluations of transforaminal lumbar interbody fusion (TLIF) versus Posterior lumbar interbody fusion (PLIF) in adults with lumbar spondylolisthesis: A systematic review.

Inge J M H Caelers1,2,3, Suzanne L de Kunder4, Kim Rijkers2,3, Wouter L W van Hemert5, Rob A de Bie1,6, Silvia M A A Evers7,8, Henk van Santbrink1,2,3.   

Abstract

INTRODUCTION: The demand for spinal fusion surgery has increased over the last decades. Health care providers should take costs and cost-effectiveness of these surgeries into account. Open transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) are two widely used techniques for spinal fusion. Earlier research revealed that TLIF is associated with less blood loss, shorter surgical time and sometimes shorter length of hospital stay, while effectiveness of both techniques on back and/or leg pain are equal. Therefore, TLIF could result in lower costs and be more cost-effective than PLIF. This is the first systematic review comparing direct and indirect (partial) economic evaluations of TLIF with PLIF in adults with lumbar spondylolisthesis. Furthermore, methodological quality of included studies was assessed.
METHODS: Searches were conducted in eight databases for reporting on eligibility criteria; TLIF or PLIF, lumbar spondylolisthesis or lumbar instability, and cost. Costs were converted to United States Dollars with reference year 2020. Study quality was assessed using the bias assessment tool of the Cochrane Handbook for Systematic Reviews of Interventions, the Level of Evidence guidelines of the Oxford Centre for Evidence-based Medicine and the Consensus Health Economic Criteria (CHEC) list.
RESULTS: Of a total of 693 studies, 16 studies were included. Comparison of TLIF and PLIF could only be made indirectly, since no study compared TLIF and PLIF directly. There was a large heterogeneity in health care and societal perspective costs due to different in-, and exclusion criteria, baseline characteristics and the use of costs or charges in calculations. Health care perspective costs, calculated with hospital costs, ranged from $15,867-$43,217 in TLIF-studies and $32,662 in one PLIF-study. Calculated with hospital charges, it ranged from $8,964-$51,469 in TLIF-studies and $21,838-$93,609 in two PLIF-studies. Societal perspective costs and cost-effectiveness, only mentioned in TLIF-studies, ranged from $5,702/QALY-$48,538/QALY and $50,092/QALY-$90,977/QALY, respectively. Overall quality of studies was low.
CONCLUSIONS: This systematic review shows that TLIF and PLIF are expensive techniques. Moreover, firm conclusions about the preferable technique, based on (partial) economic evaluations, cannot be drawn due to limited studies and heterogeneity. Randomized prospective trials and full economical evaluations with direct TLIF and PLIF comparison are needed to obtain high levels of evidence. Furthermore, development of guidelines to perform adequate economic evaluations, specified for the field of interest, will be useful to minimize heterogeneity and maximize transferability of results. TRIAL REGISTRATION: Prospero-database registration number: CRD42020196869.

Entities:  

Mesh:

Year:  2021        PMID: 33571291      PMCID: PMC7877595          DOI: 10.1371/journal.pone.0245963

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  45 in total

Review 1.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

2.  Spinal fusion in the United States: analysis of trends from 1998 to 2008.

Authors:  Sean S Rajaee; Hyun W Bae; Linda E A Kanim; Rick B Delamarter
Journal:  Spine (Phila Pa 1976)       Date:  2012-01-01       Impact factor: 3.468

Review 3.  How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3).

Authors:  F W Thielen; Gapg Van Mastrigt; L T Burgers; W M Bramer; Hjm Majoie; Smaa Evers; J Kleijnen
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2016-11-02       Impact factor: 2.217

4.  The distinction between cost and charges.

Authors:  S A Finkler
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

5.  A retrospective review comparing two-year patient-reported outcomes, costs, and healthcare resource utilization for TLIF vs. PLF for single-level degenerative spondylolisthesis.

Authors:  Elliott Kim; Silky Chotai; David Stonko; Joseph Wick; Alex Sielatycki; Clinton J Devin
Journal:  Eur Spine J       Date:  2017-06-05       Impact factor: 3.134

6.  Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis.

Authors:  Owoicho Adogwa; Scott L Parker; Brandon J Davis; Oran Aaronson; Clinton Devin; Joseph S Cheng; Matthew J McGirt
Journal:  J Neurosurg Spine       Date:  2011-05-06

7.  Transforaminal lumbar interbody fusion vs. posterolateral instrumented fusion: cost-utility evaluation along side an RCT with a 2-year follow-up.

Authors:  A Christensen; K Høy; C Bünger; P Helmig; E S Hansen; T Andersen; R Søgaard
Journal:  Eur Spine J       Date:  2014-02-21       Impact factor: 3.134

8.  Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey.

Authors:  Niels Henrik Hjollund; Finn Breinholt Larsen; Johan Hviid Andersen
Journal:  Scand J Public Health       Date:  2007       Impact factor: 3.021

9.  Comparison of low back fusion techniques: transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF) approaches.

Authors:  Chad D Cole; Todd D McCall; Meic H Schmidt; Andrew T Dailey
Journal:  Curr Rev Musculoskelet Med       Date:  2009-04-29

10.  Lumbar spine surgery across 15 years: trends, complications and reoperations in a longitudinal observational study from Norway.

Authors:  Margreth Grotle; Milada Cvancarova Småstuen; Olaf Fjeld; Lars Grøvle; Jon Helgeland; Kjersti Storheim; Tore K Solberg; John-Anker Zwart
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.